While Eli Lilly's Retrutide showed headline-grabbing weight loss, a concerning 18% of patients discontinued one study due to side effects. A subsequent trial showing a much lower discontinuation rate (5%) was seen as a major win, indicating patient tolerability is now as critical as raw efficacy for commercial success.

The Lidara study showed SERD benefit in patients without pre-existing ESR1 mutations. Success is likely multifactorial: SERDs are more effective and better tolerated than AIs. Critically, they also prevent the most common resistance mechanism—the acquisition of ESR1 mutations—from developing in the first place, altering the disease's future trajectory.

The development of SERDs for adjuvant therapy was stalled for two decades not by efficacy concerns, but by logistics. Fulvestrant, the first SERD, required monthly intramuscular injections, a pragmatically unfeasible strategy for a 5-year adjuvant trial, a problem only solved with the advent of oral SERDs.

The SERINA-6 trial suggests a paradigm shift: proactively switching from an AI to an oral SERD upon detecting an ESR1 mutation in ctDNA—before clinical or radiographic progression—significantly improves progression-free survival and patient quality of life.

The failure of Roche's gerodestrant when combined with a CDK4/6 inhibitor suggests these oral SERDs may not add benefit to that backbone. This contrasts with its success alone in an adjuvant setting, reframing the drugs as an "either-or" choice rather than a combination therapy in the first-line setting.

The Phase 2 TRAIT study suggests starting adjuvant abemaciclib at a lower dose and escalating over several weeks significantly reduces early discontinuations due to side effects like diarrhea. This strategy helps more patients get through the initial high-toxicity period and remain on the effective dose for the full two-year course.

Contrary to the norm where real-world outcomes are worse than in controlled trials, real-world data for the oral SERD elacestrant shows efficacy as good as, or even better than, the pivotal EMERALD study. This unusual finding significantly bolsters confidence in the drug's broad clinical utility across a less-selected patient population.

In the EMBER-3 trial, the combination of the oral SERD imlunestrant and the CDK4/6 inhibitor abemaciclib showed a 41% reduction in progression risk versus the SERD alone. Critically, this benefit was observed regardless of the patient's ESR1 mutation status, indicating a broader mechanism of action.

Despite showing massive weight loss, new obesity drugs from Eli Lilly and others have high discontinuation rates due to side effects. This suggests the industry's singular focus on efficacy may be hitting diminishing returns, opening a new competitive front based on better patient tolerance and adherence.